What is Transgene?
Transgene operates at the intersection of genetic engineering and oncology, focusing on the design of innovative immunotherapies. The company's core value proposition lies in its ability to create personalized therapeutic vaccines, such as TG4050, and its versatile Invir.IO platform, which utilizes oncolytic viruses to target malignant cells. By integrating artificial intelligence into its myvac technology, Transgene aims to enhance the precision and efficacy of cancer treatments. The company serves a critical role in the biotechnology landscape, addressing unmet medical needs through a portfolio that emphasizes patient-specific outcomes and advanced molecular diagnostics.
How much funding has Transgene raised?
Transgene has raised a total of $144M across 2 funding rounds:
Debt
$22.4M
Stock/Share Issuance
$121.6M
Debt (2016): $22.4M with participation from European Investment Bank
Stock/Share Issuance (2025): $121.6M led by Dassault Group
Key Investors in Transgene
Dassault Group
A prominent French industrial conglomerate with deep roots in aerospace and technology, providing strategic support to high-growth enterprises.
European Investment Bank
The European Union's nonprofit long-term lending institution, focused on supporting sustainable economic development and innovation across Europe.
What's next for Transgene?
With the recent influx of capital, Transgene is expected to prioritize the advancement of its lead clinical candidates through rigorous testing phases. The strategic roadmap likely involves scaling the manufacturing capabilities required for its personalized vaccine portfolio and deepening its research into viral-based therapies. As the company moves forward, the focus will remain on achieving key regulatory milestones and potentially expanding its collaborative network to integrate further AI-driven insights into its therapeutic development cycle. This financial stability provides the necessary runway to sustain long-term innovation in the high-stakes field of cancer immunotherapy.
See full Transgene company page
